MIRA Pharma reports 100% pain signal reversal with oral Ketamir-2 in rat neuropathic pain model

MIRA PHARMACEUTICALS, INC.

Low oral doses of Ketamir-2 reversed neuropathic pain for 14-22 days in nerve-ligation rat model.
Highest dose achieved complete normalization of pain threshold, a 100% reversal of pain signal.
Oral ketamine under same conditions showed no significant pain relief, highlighting Ketamir-2's superiority.
Company plans further clinical development for Ketamir-2 as a transformative neuropathic pain treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.